- An increase in deaths from COVID-19 underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.
- Soligenix is addressing this need through the development of CiVax, its proprietary, heat-stable COVID-19 subunit vaccine candidate.
- Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants.
Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period (https://ibn.fm/viChU). However, during the same timeframe, approximately 4,500 new deaths were reported, marking a 28% increase. This underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.
In the United States, the Centers for Disease Control and Prevention (“CDC”) reported that as of April 11, 2025, the levels of acute respiratory illnesses, including COVID-19, remain low (https://ibn.fm/tTcxB). Nevertheless, the virus continues to circulate, and the potential for new variants necessitates ongoing vigilance. The fluctuating nature of COVID-19 cases and the emergence of variants highlight the critical need for continued research and development of safe and effective vaccines and therapeutics.
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is addressing this need through the development of CiVax(TM), a heat-stable COVID-19 subunit vaccine candidate. Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants (https://ibn.fm/umdje). In nonhuman primate studies, a booster dose of CiVax elicited a swift and robust neutralizing antibody response, enhancing protection against SARS-CoV-2, including the Delta and Omicron variants.
“The CiVax vaccine has demonstrated broad and robust immune responses in mice, which has been recapitulated in nonhuman primates and further shown to yield protection against infection with COVID-19 variants of concern,” observed Dr. Axel Lehrer, an associate professor at the University of Hawaiʻi at Mānoa and lead investigator in the CiVax studies. This highlights the potential of CiVax to serve as a versatile tool in the ongoing fight against COVID-19.
Soligenix’s innovative approach focuses on developing a more cost-effective vaccine that not only provides protection against multiple variants but is also thermostable, eliminating the need for cold chain storage. This characteristic is particularly advantageous for global distribution, ensuring that vaccines remain viable in regions with limited refrigeration infrastructure.
The continued prevalence of COVID-19 and the emergence of new variants underscore the importance of advancing vaccine technologies. Soligenix’s CiVax represents a promising development in this context, offering the potential for more cost-effective, broad-spectrum protection while having the logistical advantages that could significantly contribute to global vaccination efforts.
For more information, visit www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
